Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 11/20 | 1.00 |
| ▸ | GUSB | P08236 | 2/20 | 0.74 |
| ▸ | GLB1 | P16278 | 1/20 | 0.62 |
| ▸ | PYGL | P06737 | 1/20 | 0.55 |
| ▸ | GBA2 | Q9HCG7 | 9/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8181038 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8186655 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL2715246 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8181310 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8182126 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8182808 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8182197 | 1.00 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL2713123 | 0.98 | GBA1 (0.97) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8171627 | 0.93 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 | |
| SCHEMBL8186514 | 0.93 | GBA1 (1.00) | GBA1GUSBGLB1PYGLGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007150064-A2 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE | AMICUS THERAPEUTICS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |